SEARCH

SEARCH BY CITATION

References

  • 1
    Nickeleit V, Hirsch HH, Binet IF et al. Polyomavirus infection of renal allograft recipients: from latent infection to manifest disease. J Am Soc Nephrol 1999; 10: 10801089.
  • 2
    Binet I, Nickeleit V, Hirsch HH et al. Polyomavirus disease under new immunosuppressive drugs: a cause of renal graft dysfunction and graft loss. Transplantation 1999; 67: 918922.
  • 3
    Ramos E, Drachenberg CB, Papadimitriou JC et al. Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol 2002; 13: 21452151.
  • 4
    Stolt A, Sasnauskas K, Koskela P, Lehtinen M, Dillner J. Seroepidemiology of the human polyomaviruses. J Gen Virol 2003; 84: 14991504.
  • 5
    Brennan DC, Agha I, Bohl DL et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant 2005; 5: 582594.
  • 6
    Mengel M, Marwedel M, Radermacher J et al. Incidence of polyomavirus-nephropathy in renal allografts: influence of modern immunosuppressive drugs. Nephrol Dial Transplant 2003; 18: 11901196.
  • 7
    Hirsch HH, Brennan DC, Drachenberg CB et al. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation 2005; 79: 12771286.
  • 8
    Celik B, Shapiro R, Vats A, Randhawa PS. Polyomavirus allograft nephropathy: sequential assessment of histologic viral load, tubulitis, and graft function following changes in immunosuppression. Am J Transplant 2003; 3: 13781382.
  • 9
    Drachenberg CB, Papadimitriou JC, Hirsch HH et al. Histological patterns of polyomavirus nephropathy: correlation with graft outcome and viral load. Am J Transplant 2004; 4: 20822092.
  • 10
    Amyes E, Hatton C, Montamat-Sicotte D et al. Characterization of the CD4+ T-cell response to Epstein-Barr virus during primary and persistent infection. J Exp Med 2003; 198: 903911.
  • 11
    Bunde T, Kirchner A, Hoffmeister B et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 2005; 201: 10311036.
  • 12
    Drachenberg CB, Papadimitriou JC, Hirsch HH et al. Histological patterns of polyomavirus nephropathy: correlation with graft outcome and viral load. Am J Transplant 2004; 4: 20822092.
  • 13
    Comoli P, Basso S, Azzi A et al. Dendritic cells pulsed with polyomavirus BK antigen induce ex vivo polyoma BK virus-specific cytotoxic T-cell lines in seropositive healthy individuals and renal transplant recipients. J Am Soc Nephrol 2003; 14: 31973204.
  • 14
    Comoli P, Azzi A, Maccario R et al. Polyomavirus BK-specific immunity after kidney transplantation. Transplantation 2004; 78: 12291232.
  • 15
    Kern F, Faulhaber N, Frommel C et al. Analysis of CD8 T-cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. Eur J Immunol 2000; 30: 16761682.
  • 16
    Bunde T, Kirchner A, Hoffmeister B et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 2005; 201: 10311036.
  • 17
    Tesfa L, Koch FW, Pankow W, Volk HD, Kern F. Confirmation of Mycobacterium tuberculosis infection by flow cytometry after ex vivo incubation of peripheral blood T cells with an ESAT-6-derived peptide pool. Cytometry 2004; 60B: 4753.
  • 18
    Stolt A, Sasnauskas K, Koskela P, Lehtinen M, Dillner J. Seroepidemiology of the human polyomaviruses. J Gen Virol 2003; 84: 14991504.
  • 19
    Beattie T, Kaul R, Rostron T et al. Screening for HIV-specific T-cell responses using overlapping 15-mer peptide pools or optimized epitopes. AIDS 2004; 18: 15951598.